Novartis (SWX:NOVN) acquired an exclusive global license, excluding Canada, to CELG's d-methylphenidate, a chirally pure form of Ritalin, to treat attention deficit disorder and attention deficit hyperactivity
Read the full 279 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury